Exposure to intravenous posaconazole in critically ill patients with influenza: A pharmacokinetic analysis of the POSA-FLU study

Ruth Van Daele, Joost Wauters, Erwin Dreesen, Jerina Boelens, Eric Nulens, Piet Lormans, Lore Vanderbeke, Cato Jacobs, Bart Rijnders, Paul E. Verweij, Roger J. Brüggemann, Isabel Spriet

Research output: Contribution to journalArticlepeer-review

5 Citations (Scopus)

Abstract

Background: Data on posaconazole in the critically ill are scarce. In the POSA-FLU study, we examined the prevention of influenza-associated pulmonary aspergillosis with posaconazole in this population. Methods: In this observational sub-study, we performed a pharmacokinetic analysis, including protein binding and target attainment (TA). Blood samples were collected over a 24 h-dosing interval on both an early (Day 2 or 3) and a later (≥Day 4) treatment day. Results: Target attainment was shown for AUC0-24 and Cmin prophylaxis but not for Cmin treatment. Moreover, a saturable protein binding with a significant, positive relationship between albumin concentrations and the maximum binding capacity was observed. Conclusions: Our analysis indicates that posaconazole may be a suitable drug to further investigate for prophylaxis, as TA for prophylaxis was reached. Exposure targets for treatment were insufficiently attained in this population.

Original languageEnglish
Pages (from-to)656-660
Number of pages5
JournalMycoses
Volume65
Issue number6
DOIs
Publication statusPublished - Jun 2022
Externally publishedYes

Keywords

  • critically ill patients
  • exposure
  • posaconazole
  • target attainment
  • unbound concentrations
  • Administration, Intravenous
  • Triazoles
  • Humans
  • Influenza, Human/drug therapy
  • Antifungal Agents
  • Critical Illness/therapy

Fingerprint

Dive into the research topics of 'Exposure to intravenous posaconazole in critically ill patients with influenza: A pharmacokinetic analysis of the POSA-FLU study'. Together they form a unique fingerprint.

Cite this